|
|
 Previous Article | Table of Contents | Next Article 
Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials
Arndt Borkhardt,
Giovanni Cazzaniga,
Susanne Viehmann,
Maria Grazia Valsecchi,
Wolf Dieter Ludwig,
Linda Burci,
Silvia Mangioni,
Martin Schrappe,
Hansjörg Riehm,
Fritz Lampert,
Giuseppe Basso,
Giuseppe Masera,
Jochen Harbott, and
Andrea Biondi for the "Associazione Italiana Ematologia Oncologia Pediatrica" and the "Berlin-Frankfurt-Münster" Study Group
From the Department of General Pediatrics, Hematology, and Oncology, Children's University Hospital Giessen, Germany; Clinica Pediatrica Università di Milano, Ospedale S.Gerardo, Monza, Italy; Robert Rössle Clinic, Free University of Berlin, Berlin, Germany; Department of Pediatrics IV, Hannover Medical School, Hannover, Germany; Clinica Pediatrica Università di Torino, Torino, Italy; Istituto di Statistica Medica e Biometria, Università di Milano, Milano, Italy.
The molecular approach for the analysis of leukemia associated chromosomal translocations has led to the identification of prognostic relevant subgroups. In pediatric acute lymphoblastic leukemia (ALL), the most common translocations, t(9; 22) and t(4; 11), have been associated with a poorer clinical outcome. Recently the TEL gene at chromosome 12p13 and the AML1 gene at chromosome 21q22 were found to be involved in the translocation t(12; 21)(p13; q22). By conventional cytogenetics, however, this chromosomal abnormality is barely detectable and occurs in less than 0.05% of childhood ALL. To investigate the frequency of the molecular equivalent of the t(12; 21), the TEL/AML1 gene fusion, we have undertaken a prospective screening in the running German Berlin-Frankfurt-Münster (BFM) and Italian Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) multicenter ALL therapy trials. We have analyzed 334 unselected cases of pediatric ALL patients consecutively referred over a period of 5 and 9 months, respectively. The overall incidence of the t(12; 21) in pediatric ALL is 18.9%. The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype. Interestingly, one case displayed a pre-pre-B immunophenotype. Among the B-lineage subgroup, the t(12; 21) occurs in 22.0% of the cases. Fifteen of 61 (24.6%) cases coexpressed at least two myeloid antigens (CD13, CD33, or CDw65) in more than 20% of the gated blast cells. DNA index was available for 59 of the 63 TEL/AML1 positive cases; a hyperdiploid DNA content ( 1.16) was detected in only four patients, being nonhyperdiploid in the remaining 55. Based on this prospective analysis, we retrospectively evaluated the impact of TEL/AML1 in prognosis by identifying the subset of B-lineage ALL children enrolled in the closed German ALL-BFM-90 and Italian ALL-AIEOP-91 protocols who had sufficient material for analysis. A total of 342 children were investigated for the presence of TEL/AML1 fusion gene and 99 cases (28.9%) were positive. The patients expressing the TEL/AML1 fusion mRNA appeared to have a better event-free survival (EFS) than the patients who lacked this chimeric product. Whereas three of the TEL/AML1 positive cases (3.0%) have relapsed to date, 27 patients without TEL/AML1 rearrangement (11.1%) suffered from relapse. To date, the only subset of B-lineage ALL with a favorable prognosis has been the hyperdiploid group (DNA index 1.16 <1.6). Our findings reinforce the need to include the molecular screening of the t(12; 21) translocation within ongoing prospective ALL trials to prove definitively its prognostic impact.
Blood, Vol. 90 No. 2 (July 15), 1997:
pp. 571-577
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood,
July 30, 2009;
114(5):
937 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Teuffel, M. Stanulla, G. Cario, W. D. Ludwig, S. Rottgers, B. W. Schafer, M. Zimmermann, M. Schrappe, and F. K. Niggli
Anemia and survival in childhood acute lymphoblastic leukemia
Haematologica,
November 1, 2008;
93(11):
1652 - 1657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moricke, A. Reiter, M. Zimmermann, H. Gadner, M. Stanulla, M. Dordelmann, L. Loning, R. Beier, W.-D. Ludwig, R. Ratei, et al.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Blood,
May 1, 2008;
111(9):
4477 - 4489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ibrahim, S. S. Daud, Y.-L. Seah, A. E. Yeoh, H. Ariffin, and for the Malaysia-Singapore Leukemia Study Group
Rapid Detection of Prognostically Important Childhood Acute Lymphoblastic Leukemia Chimeric Transcripts Using Multiplex SYBR Green Real-Time Reverse Transcription PCR
Ann. Clin. Lab. Sci.,
January 1, 2008;
38(4):
338 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Accordi, S. Pillozzi, M. C. Dell'Orto, G. Cazzaniga, A. Arcangeli, G. t. Kronnie, and G. Basso
Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation
J. Biol. Chem.,
October 5, 2007;
282(40):
29384 - 29393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, M. J. Calasanz, L. Garate, E. San Jose-Eneriz, L. Cordeu, F. Prosper, et al.
CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4845 - 4850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Armstrong and A. T. Look
Molecular Genetics of Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6306 - 6315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al.
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Blood,
July 15, 2005;
106(2):
494 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. DeAngelo
The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Hematology,
January 1, 2005;
2005(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-M. Frost, E. Forestier, G. Gustafsson, P. Nygren, M. Hellebostad, O. G. Jonsson, J. Kanerva, K. Schmiegelow, R. Larsson, G. Lonnerholm, et al.
Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia
Blood,
October 15, 2004;
104(8):
2452 - 2457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Zaza, W. Yang, L. Kager, M. Cheok, J. Downing, C.-H. Pui, C. Cheng, M. V. Relling, and W. E. Evans
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis
Blood,
September 1, 2004;
104(5):
1435 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zuna, A. M. Ford, M. Peham, N. Patel, V. Saha, C. Eckert, J. Kochling, R. Panzer-Grumayer, J. Trka, and M. Greaves
TEL Deletion Analysis Supports a Novel View of Relapse in Childhood Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
August 15, 2004;
10(16):
5355 - 5360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Weber, P. Imisch, E. Bergmann, and H. Christiansen
Coamplification of DDX1 Correlates With an Improved Survival Probability in Children With MYCN-Amplified Human Neuroblastoma
J. Clin. Oncol.,
July 1, 2004;
22(13):
2681 - 2690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morrow, S. Horton, D. Kioussis, H. J. M. Brady, and O. Williams
TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity
Blood,
May 15, 2004;
103(10):
3890 - 3896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. G. Stams, M. L. den Boer, H. B. Beverloo, J. P. P. Meijerink, R. L. Stigter, E. R. van Wering, G. E. Janka-Schaub, R. Slater, and R. Pieters
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL
Blood,
April 1, 2003;
101(7):
2743 - 2747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Boissel, M.-F. Auclerc, V. Lheritier, Y. Perel, X. Thomas, T. Leblanc, P. Rousselot, J.-M. Cayuela, J. Gabert, N. Fegueux, et al.
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
J. Clin. Oncol.,
March 1, 2003;
21(5):
774 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hotfilder, S. Rottgers, A. Rosemann, H. Jurgens, J. Harbott, and J. Vormoor
Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal
Blood,
June 28, 2002;
100(2):
640 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Weston, C. M. McConville, J. R. Mann, P. J. Darbyshire, S. Lawson, J. Gordon, P. A. H. Moss, A. Malcolm, R. Taylor, and T. Stankovic
Molecular Analysis of Single Colonies Reveals a Diverse Origin of Initial Clonal Proliferation in B-Precursor Acute Lymphoblastic Leukemia that Can Precede the t(12;21) Translocation
Cancer Res.,
December 1, 2001;
61(23):
8547 - 8553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, A. V. Stackelberg, T. Taube, D. Buchwald, G. Korner, M. Suttorp, W. Dorffel, W. Tausch, and G. Henze
Relapse of TEL-AML1-Positive Acute Lymphoblastic Leukemia in Childhood: A Matched-Pair Analysis
J. Clin. Oncol.,
July 1, 2001;
19(13):
3188 - 3193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, K.-A. Kreuzer, U. Lass, T. Taube, D. Buchwald, C. Eckert, G. Körner, C.-A Schmidt, and G. Henze
Molecular Quantification of Response to Therapy and Remission Status in TEL-AML1-Positive Childhood ALL by Real-Time Reverse Transcription Polymerase Chain Reaction
Cancer Res.,
March 1, 2001;
61(6):
2517 - 2522.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. B. Silverman, R. D. Gelber, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, M. A. Schorin, et al.
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
Blood,
March 1, 2001;
97(5):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Brumpt, E. Delabesse, K. Beldjord, F. Davi, J.-M. Cayuela, C. Millien, P. Villarese, P. Quartier, A. Buzyn, F. Valensi, et al.
The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype
Blood,
September 15, 2000;
96(6):
2254 - 2261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. R.-v. Woerden, R. Pieters, A. H. Loonen, I. Hubeek, E. van Drunen, H. B. Beverloo, R. M. Slater, J. Harbott, J. Seyfarth, E. R. van Wering, et al.
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
Blood,
August 1, 2000;
96(3):
1094 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schrappe, A. Reiter, W.-D. Ludwig, J. Harbott, M. Zimmermann, W. Hiddemann, C. Niemeyer, G. Henze, A. Feldges, F. Zintl, et al.
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90
Blood,
June 1, 2000;
95(11):
3310 - 3322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Toyoda, A. Manabe, M. Tsuchida, R. Hanada, K. Ikuta, Y. Okimoto, A. Ohara, Y. Ohkawa, T. Mori, K. Ishimoto, et al.
Six Months of Maintenance Chemotherapy After Intensified Treatment for Acute Lymphoblastic Leukemia of Childhood
J. Clin. Oncol.,
April 7, 2000;
18(7):
1508 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O B Eden
Therapeutic trials in childhood ALL: what's their future?
J. Clin. Pathol.,
January 1, 2000;
53(1):
55 - 59.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Knuutila, Y. Aalto, K. Autio, A.-M. Bjorkqvist, W.'e. El-Rifai, S. Hemmer, T. Huhta, E. Kettunen, S. Kiuru-Kuhlefelt, M. L. Larramendy, et al.
DNA Copy Number Losses in Human Neoplasms
Am. J. Pathol.,
September 1, 1999;
155(3):
683 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Wiemels, A. M. Ford, E. R. Van Wering, A. Postma, and M. Greaves
Protracted and Variable Latency of Acute Lymphoblastic Leukemia After TEL-AML1 Gene Fusion In Utero
Blood,
August 1, 1999;
94(3):
1057 - 1062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Thandla, J. E. Ploski, S. Z. Raza-Egilmez, P. P. Chhalliyil, A. W. Block, P. J. de Jong, and P. D. Aplan
ETV6-AML1 Translocation Breakpoints Cluster Near a Purine/Pyrimidine Repeat Region in the ETV6 Gene
Blood,
January 1, 1999;
93(1):
293 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Loh, L. B. Silverman, M. L. Young, D. Neuberg, T. R. Golub, S. E. Sallan, and D. G. Gilliland
Incidence of TEL/AML1 Fusion in Children With Relapsed Acute Lymphoblastic Leukemia
Blood,
December 15, 1998;
92(12):
4792 - 4797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 27, 1998;
339(9):
605 - 615.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Putti, R. Rondelli, M. G. Cocito, M. Arico, L. Sainati, V. Conter, C. Guglielmi, A. Cantu-Rajnoldi, R. Consolini, A. Pession, et al.
Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies
Blood,
August 1, 1998;
92(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, H. M. Kantarjian, M. Talpaz, and Z. Estrov
Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Blood,
June 1, 1998;
91(11):
3995 - 4019.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, H.-P. Adams, D. Buchwald, B. Beyermann, B. Kremens, C. Niemeyer, J. Ritter, D. Schwabe, D. Harms, M. Schrappe, et al.
TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia
Blood,
March 1, 1998;
91(5):
1716 - 1722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Rubnitz and C.-H. Pui
Childhood Acute Lymphoblastic Leukemia
Oncologist,
December 1, 1997;
2(6):
374 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Look
Oncogenic Transcription Factors in the Human Acute Leukemias
Science,
November 7, 1997;
278(5340):
1059 - 1064.
[Abstract]
[Full Text]
|
|
|
|
|
